Shahin Akhondzadeh

Shahin Akhondzadeh

Auto-generated profile, based on publicly available information

Shahin Akhondzadeh

Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2009 in Depression and Anxiety
Verified
Journal Article
Open access
PDF file
SAShahin Akhondzadeh
Shahin Akhondzadeh
SJSara Jafari
Sara Jafari
FRFiroozeh Raisi
Firoozeh Raisi
ANAbbas Ali Nasehi
Abbas Ali Nasehi
AGAboulfazl Ghoreishi
Aboulfazl Ghoreishi
AKAbbas Kamalipour
Abbas Kamalipour
Background: The pathophysiology of depression is associated with the hyperactivity of immune inflammatory responses. Cyclooxygenase-2 inhibitors such as celecoxib reduce the production of pro-inflammatory cytokines. The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of major depression in a six-week double blind and placebo controlled trial. Methods: Forty adult outpatients who met the DSM-IV-TR criteria for major depression participated in the trial. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18. Patients were allocated in a random fashion: 20 to fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 20 to fluoxetine 40 mg/day plus placebo. Patients were assessed by a psychiatrist at baseline and after 1, 2, 4, and 6 weeks after the medication started. Results: Although both protocols significantly decreased the score of Hamilton Rating Scale for Depression over the trial period, the combination of fluoxetine and celecoxib showed a significant superiority over fluoxetine alone in the treatment of symptoms of major depression. There were no significant differences in the two groups in terms of observed side effects. Conclusion: The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with major depression and anti-inflammatory therapies should be further investigated. Depression and Anxiety, 2009.

1 December 2012 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SASeyed-Hesameddin Abbasi
Seyed-Hesameddin Abbasi
FHFahimeh Hosseini
Fahimeh Hosseini
AMAmirhossein Modabbernia
Amirhossein Modabbernia
MAMandana Ashrafi
Mandana Ashrafi
SAShahin Akhondzadeh
Shahin Akhondzadeh

28 February 2003 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
SAS. Akhondzadeh
S. Akhondzadeh
MNM. Noroozian
M. Noroozian
MMM. Mohammadi
M. Mohammadi
SOS. Ohadinia
S. Ohadinia
AJA. H. Jamshidi
A. H. Jamshidi
MKM. Khani
M. Khani
Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. Acetylcholine esterase inhibitors are the only agents approved by the Food and Drug Administration for the treatment of Alzheimer's disease. All other agents prescribed for the treatment of Alzheimer's disease are used on an off-label basis. Current research into new drugs is focused on agents that will prevent, slow down and/or halt the progress of the disease process. Salvia officinalis has been used in herbal medicine for many centuries. It has been suggested, on the basis of traditional medicine, its in vitro cholinergic binding properties and modulation of mood and cognitive performance in humans, that Salvia officinalis might potentially provide a novel natural treatment for Alzheimer's disease. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract using a fixed dose (60 drops/day), in patients with mild to moderate Alzheimer's disease, over a 4-month period. This was a 4-month, parallel group, placebo-controlled trial undertaken in three centres in Tehran, Iran. Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42, 18 women) with a score of > or = 12 on the cognitive subscale of Alzheimer's Disease Assessment Scale (ADAS-cog) and < or = 2 on the Clinical Dementia Rating (CDR) were randomized to placebo or fixed dose of S. officinalis extract. Over the 16 weeks, the main efficacy measures were the change in the ADAS-cog and CDR-Sum of Boxes scores compared with baseline. In addition, side-effects were systematically recorded throughout the study using a checklist. At 4 months, S. officinalis extract produced a significant better outcome on cognitive functions than placebo (ADAS-cog: F = 4.77, d.f. = 1, P = 0.03) (CDR-SB: F = 10.84, d.f. = 1, P < 0.003). There were no significant differences in the two groups in terms of observed side-effects except agitation that appears to be more frequent in the placebo group (P = 0.09). The results of this study indicate the efficacy of S. officinalis extract in the management of mild to moderate Alzheimer's disease. Moreover, S. officinalis may well reduce agitation of patients but this needs to be confirmed.

1 February 2005 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ANA.A. Noorbala
A.A. Noorbala
SAS. Akhondzadeh
S. Akhondzadeh
NTN. Tahmacebi-Pour
N. Tahmacebi-Pour
AJA.H. Jamshidi
A.H. Jamshidi

1 February 2005 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SAShahin Akhondzadeh
Shahin Akhondzadeh
NTNajaf Tahmacebi‐Pour
Najaf Tahmacebi‐Pour
ANAhamad‐Ali Noorbala
Ahamad‐Ali Noorbala
HAHomayoun Amini
Homayoun Amini
HFHassan Fallah‐Pour
Hassan Fallah‐Pour
MKMousa Khani
Mousa Khani

1 February 2007 in Schizophrenia Research
Verified
Journal Article
Closed access
SAS Akhondzadeh
S Akhondzadeh
MTM Tabatabaee
M Tabatabaee
HAH Amini
H Amini
SAS Ahmadiabhari
S Ahmadiabhari
SAS Abbasi
S Abbasi
BBB Behnam
B Behnam